SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether sunitinib (SU011248) has activity and is safe in
patients with renal cell carcinoma (RCC) who have failed prior therapy with bevacizumab
(Avastin) -based treatment.